The overall purpose of this project is to better understand the epidemiology of COVID-19in patients with hematological malignancies (including hematopoietic stem cell transplantrecipients) in the different European Countries. The results obtained will allow us tobetter know the prevalence of this complication in the different categories of patientswith hematological malignancies (HMs). In order to attain the objectives previouslydescribed we will develop a multicentre, international, observational, retrospective andprospective study of consecutive cases of COVID-19 among HMs. There will be a clinicalfollow-up of the patients included in this study to observe the survival rate. Datacollected form this study will be evaluated with a descriptive analysis.
At the moment, few data on the epidemiology of SARS-CoV-2 infection in patients suffering
from hematological malignancies are available. However, the COVID-19 pandemic presents
unique challenges and opportunities on hematological malignancies. The future trajectory
of this pandemic appears to be growing and hematology communities must continue to
prepare for its spread In this project, we will implement cooperation between all members
of the hematology departments both within the EHA and outside it, in order to evaluate
the epidemiological data on the incidence and outcome in patients with hematological
malignancies infected with SARS-CoV-2.
We will provide useful information to inform the individualized plan for patients with
hematological malignancies.
We aim to evaluate the epidemiology and outcomes of patients with HM infected with
COVID-19,estimate the incidence and type of disease, assess the acute and long-term
mortality rate and estimate the overall mortality rate of cases.
This is a cohort retrospective/prospective survey. In the retrospective phase of the
study, participating centers will retrospectively review episodes of COVID-19 disease
that occurred in patients with hematological malignancies identified at their
institutions from February 2020 to December 2020. In the prospective phase of the study,
the researchers will include episodes of COVID-19 disease from the start of the study
through December 31, 2021.
The study population will need to be over 18 with hematological malignancies and
SARS-CoV-2 An electronic database with anonymization will be created and available to
collect all information with single access for each participating institution. The data
collected will be demographic data,epidemiological factors, admission information,
COVID-19 disease severity, history of hematological malignancies, disease status with
past / current treatments, and 30 days of diagnosis.
Inclusion Criteria:
- Age equal to or greater than 18 years of age.
- History of hematological malignancies (acute leukemias, myelodysplastic syndromes,
myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative
disorders) at any stage/status.
- Active hematological malignancies at any stage/status.
- Diagnosis of hematological malignancy (acute leukemias, myelodysplastic syndromes,
myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative
disorders) at any stage/status.
- SARS-CoV-2 positive test (nasopharyngeal, BAL, fecal), documented by Real-Time
Reverse Transcriptase (RT)-PCR Diagnostic Panels.
Exclusion Criteria:
- Hematological diseases, other than hematological malignancies.
- Not tested positive for SARS-CoV-2
- Patients "off therapy" for more than 5 years
ASST-Spedali Civili
Brescia, Italy
AOU Policlinico Federico II
Napoli, Italy
Fondazione Policlinico A. Gemelli IRCCS
Rome, Italy
Istituto Nazionale Tumori Regina Elena IFO
Rome, Italy
Osp. di Circolo-Fondazione Macchi
Varese, Italy
AOUI Verona
Verona, Italy
livio pagano, Prof
+390630154180
livio.pagano@unicatt.it
Jon Salmanton Garcia, Dr
jon.salmanton-garcia@uk-koeln.de